Proactive Investors - Run By Investors For Investors

Amryt Pharma looking to replicate success of Lojuxta drug

Amryt Pharma PLC's (LON:AMYT) Rory Nealon tells Proactive that the company is actively seeking to expand its commercial portfolio following the success of its Lojuxta treatment.

The pharmaceutical firm reported a narrowed loss before tax of €11.3mln for the first half of the year, less than a €13.8mln loss previously, while revenues grew to €7mln from €6.1mln.

Revenues were boosted by a 14.6% increase in sales of the Lojuxta drug to €6.6mln.

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use